Source:http://linkedlifedata.com/resource/pubmed/id/19886071
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2009-11-4
|
pubmed:abstractText |
The inflammatory reaction is characterized by increased circulatory levels of various indicators of the severity of inflammation. The objective was to investigate the value of lipoprotein-associated phospholipase A2 (Lp-PLA2) in patients with noncardioembolic ischemic stroke and severe proinflammatory reaction. There were investigated prospectively Lp-PLA2 levels in sera from 47 patients with ischemic stroke and severe inflammatory reaction (32 men and 15 women, mean age 63 +/- 4.23 years) as compared to 38 patients with ischemic stroke without inflammatory reaction (21 men and 17 women, mean age 61 +/- 5.52 years) and 114 healthy elderly controls. Lp-PLA2 levels were assessed using the diaDexus PLAC test (a noncompetitive ELISA). Out of 47 patients with ischemic stroke and severe inflammatory reaction 36 presented Lp-PLA2 high levels (79%). Lp-PLA2 was detected with high levels in 17 out of 30 patients with ischemic stroke without inflammatory reaction (45%). Patients with ischemic stroke and severe inflammatory reaction presented Lp-PLA2 with high levels more frequently than the healthy controls (RR 12.1 [95% CI. 6.22 to 19.333], p<0.0001). Levels of Lp-PLA2 were higher in subjects who experienced a stroke as compared to controls. Lp-PLA2 is a strong predictor of recurrent stroke risk and of increased risk of dying. The determination of Lp-PLA2 should be used to predict patient risk of cardiovascular disease and stroke; it does provide additional risk of inflammation when used in conjunction with the traditional markers. Lp-PLA2 might be used not only for risk stratification of stroke patients, but also as target for treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1220-4749
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
61-5
|
pubmed:meshHeading |
pubmed-meshheading:19886071-1-Alkyl-2-acetylglycerophosphocholine Esterase,
pubmed-meshheading:19886071-Aged,
pubmed-meshheading:19886071-Biological Markers,
pubmed-meshheading:19886071-Brain Ischemia,
pubmed-meshheading:19886071-Case-Control Studies,
pubmed-meshheading:19886071-Female,
pubmed-meshheading:19886071-Humans,
pubmed-meshheading:19886071-Inflammation,
pubmed-meshheading:19886071-Male,
pubmed-meshheading:19886071-Middle Aged,
pubmed-meshheading:19886071-Prospective Studies,
pubmed-meshheading:19886071-Risk Factors,
pubmed-meshheading:19886071-Stroke
|
pubmed:year |
2009
|
pubmed:articleTitle |
Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction.
|
pubmed:affiliation |
"Carol Davila" University of Medicine and Pharmacy, Department of Neurology, Colentina Clinical Hospital, Bucharest, Romania. mcojocar@cmb.ro
|
pubmed:publicationType |
Journal Article
|